


Branimir I. Sikic, M. D.

Professor of Medicine (Oncology), Emeritus

Medicine - Oncology

 Curriculum Vitae available Online

 Resume available Online

CONTACT INFORMATION

• Administrative Contact

Administrative assistant

Tel 650-723-5290

Bio

BIO

Branimir I. (Brandy) Sikic, M. D., is Professor of Medicine in the Division of Oncology at Stanford University School of Medicine. He was Director of the General Clinical Research Center and then Co-director of the Stanford University Center for Clinical and Translational Education and Research (Spectrum) and Director of the Stanford Clinical and Translational Research Unit (CTRU) from 1992-2017. He received his undergraduate education at Georgetown University, and an M. D. from the University of Chicago. He returned to Georgetown for his residency in internal medicine, and performed a research fellowship in cancer pharmacology at the National Cancer Institute and in medical oncology at Georgetown prior to his appointment to the Stanford University faculty in 1979. He has authored more than 250 publications, edited two books, and is the inventor of two U.S. patents. His publications have been cited more than 13,300 times and their research impact is very high, with an h-factor of 65. He has served on several advisory committees of the National Institutes of Health, including as chairman of the Experimental Therapeutics I Study Section. In 2005-6 he chaired the Scientific Program Committee for the American Society of Clinical Oncology (ASCO), and in 2008-9 was co-chair of the Program Committee of the American Association for Cancer Research (AACR). He founded the Central European Oncology Congress, held in Opatija, Croatia, and has directed it since 1998. In 2010 he was awarded the Katarina Zrinska medal for science and medicine by the president of Croatia. Dr. Sikic is a leader in the pharmacology of anticancer drugs and the development of new cancer therapies. His laboratory and clinical research programs closed in 2018. His research spanned the spectrum from molecular and genetic approaches in cancer cells to clinical trials in cancer patients. Dr. Sikic's laboratory studied mechanisms of drug resistance in cancer cells and the development of more effective cancer therapies. He has made major contributions to understanding the problem of multidrug resistance in cancer cells, tubulin dynamicity, IAP inhibitors, and the CCL2/CCR2 pathway. His most recent clinical trials of new anticancer drugs included Phase 1 studies of antibodies activating the T-cell regulating CD27 pathway and the macrophage regulating CD47 pathway.

ACADEMIC APPOINTMENTS

- Emeritus Faculty, Acad Council, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Scientific Program Committee Chair, American Society of Clinical Oncology, (2005-2006)
- Director, Clinical and Translational Research Unit, Stanford University, (2008-2017)

- Co-Director, Stanford Center for Clinical and Translational Education and Research, Stanford University, (2008-2017)

HONORS AND AWARDS

- Pfizer Visiting Professor in Clinical Pharmacology, Dartmouth University (1992)
- 70th Anniversary of the CRC lecture, British Association of Cancer Research (1993)
- Plenary lecturer in drug resistance, Netherlands Cancer Institute (1999)
- Oncology Teaching Award, Oncology Division, Stanford (2000)
- Best Doctors in America, "Best Doctors" annual survey (2002-13)
- John H. Blaffer Visiting Professor, M.D. Anderson Cancer Center (2003)
- Statesman Award, American Society of Clinical Oncology (2010)
- Presidential Medal for Science and Medicine, Government of Croatia (2010)

PROFESSIONAL EDUCATION

- Fellowship: Georgetown University Hospital (1979) DC
- Residency: Georgetown University Hospital (1975) DC
- Board Recertification, Medical Oncology, American Board of Internal Medicine (2010)
- Board Certification: Medical Oncology, American Board of Internal Medicine (1979)
- Fellowship: National Cancer Institute (1978) MD
- Board Certification: Internal Medicine, American Board of Internal Medicine (1975)
- Medical Education: University of Chicago School of Medicine (1972) IL
- B.S., Georgetown University, Biology (1968)
- M.D., University of Chicago, Medicine (1972)

COMMUNITY AND INTERNATIONAL WORK

- Central European Oncology Congress, Opatija, Croatia

PATENTS

- Branimir Sikic. "United States Patent 7,875,274 Protein Modulators of Resistance to Alkylating Agents", Leland Stanford Junior University, Jan 25, 2011
- Branimir Sikic, Kevin Chen. "United States Patent 5,830,697 P-Glycoprotein Mutant Resistant to Cyclosporin Modulation", Leland Stanford Junior University, Nov 3, 1998

LINKS

- Stanford Medical School - Sikic Laboratory: http://med.stanford.edu/labs/branimir_sikic/

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Our goals are to understand mechanisms of drug resistance in cancer cells and to develop more effective therapies. Current research ranges from biochemical and molecular studies in cellular models to Phase I and II clinical trials of new antibodies to activate the immune system as a cancer therapy. Our current phase I trial uses the Hu5F9-G4 monoclonal antibody discovered at Stanford, to inhibit the CD47 pathway and thus activate macrophages against cancers.

Laboratory projects include studies of the multidrug transporter P-glycoprotein, regulation of the MDR1 gene, and the role of beta tubulin gene expression in resistance to taxanes and vinca alkaloids. In addition, we are studying Hu5F9-G4 in mouse models of human ovarian cancers, used as a single agent and in combination with other antibodies and with chemotherapies.

CLINICAL TRIALS

- Cetuximab in Combination w/ Oxaliplatin, Capecitabine, & XRT Followed by Surgery for Rectal Cancer, Not Recruiting
- Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody, Not Recruiting
- Phase 1b/2 AMG 655 in Combination with AMG479 for Advanced, Refractory Solid Tumors, Not Recruiting
- Phase 2 Pilot FP-1039 in Advanced and/or Recurrent Endometrial Cancers with Specific FGFR2 Mutations, Not Recruiting
- Phase I CDX-1127 in Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors, Not Recruiting
- Phase I HGS1029 (AEG40826-2HCl) for Advanced Solid Tumors, Not Recruiting
- Phase I Ixabepilone as 3 Oral Doses Each Separated by 6 Hours Every 21 Days for Advanced Cancer , Not Recruiting
- Phase I Oblimersen + Gemcitabine in Advanced Malignancies, Not Recruiting
- Phase I OMP-21M18 in Solid Tumors, Not Recruiting
- Phase I RO5185426 in Previously Treated BRAF V600E Positive Metastatic Melanoma, Not Recruiting
- Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer, Not Recruiting
- Phase I/II Anti-CD27 Antibody(Varlilumab) + Anti-PD-1(Nivolumab) in Advanced Refractory Solid Tumors, Not Recruiting
- Phase I: Oral XL647 in Refractory Solid Tumors, Not Recruiting
- Phase III MEK162 vs Dacarbazine in Advanced Unresectable / Metastatic NRAS Mutation+ Melanoma, Not Recruiting
- Phase III Vemurafenib (RO5185426) Adjuvant Tx in Surgically Resected Cutaneous BRAF-Mutant Melanoma, Not Recruiting
- Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors, Not Recruiting
- Study of Cobimetinib in Participants With Solid Tumors, Not Recruiting
- Study of XL647 Administered Orally Daily to Patients With Solid Tumors, Not Recruiting
- Phase IB HGS1036 in Combination With Chemotherapy in Advanced Solid Malignancies, Not Specified
- Phase III Vemurafenib + Placebo vs Vemurafenib + GDC-0973 in BRAFV600-Mutation Positive Melanoma , Not Specified

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cancer Biology (Phd Program)
- Chemical and Systems Biology (Phd Program)

Publications

PUBLICATIONS

- **Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype.** *Cancer chemotherapy and pharmacology*
Marcelletti, J. F., Sikic, B. I.
2024
- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers** *JOURNAL OF CLINICAL ONCOLOGY*
Sikic, B., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019; 37 (12): 946+

- **First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
2019: JCO1802018
- **Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas.** *JCO clinical cancer informatics*
Villalobos, V. M., Wang, Y. C., Sikic, B. I.
2018: 1–16
- **Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.** *Cytometry. Part B, Clinical cytometry*
Marcelletti, J. F., Sikic, B. I., Cripe, L. D., Paietta, E.
2018
- **Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.** *Cancer chemotherapy and pharmacology*
Duran, G. E., Derdau, V., Weitz, D., Philippe, N., Blankenstein, J., Atzrodt, J., Semiond, D., Gianolio, D. A., Mace, S., Sikic, B. I.
2018; 81 (6): 1095–1103
- **Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas** *JCO CLINICAL CANCER INFORMATICS*
Villalobos, V. M., Wang, Y. C., Sikic, B.
2018
- **Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition** *BRITISH JOURNAL OF CANCER*
Duran, G. E., Wang, Y. C., Moisan, F., Francisco, E. B., Sikic, B. I.
2017; 116 (10): 1318-1328
- **The CD47 Macrophage Checkpoint as a New Immunotherapy Target**
Sikic, B. I., Padda, S. K., Shah, S. A., Colevas, D., Narayanan, S., Fisher, G. A., Supan, D., Wakelee, H. A., Aoki, R., Pegram, M. D., Villalobos, V. M., Liu, J., Takimoto, et al
ELSEVIER SCIENCE INC.2017: S108–S109
- **Chromatin-Remodeling Complex SWI/SNF Controls Multidrug Resistance by Transcriptionally Regulating the Drug Efflux Pump ABCB1** *CANCER RESEARCH*
Dubey, R., Lebensohn, A. M., Bahrami-Nejad, Z., Marceau, C., Champion, M., Gevaert, O., Sikic, B. I., Carette, J. E., Rohatgi, R.
2016; 76 (19): 5810-5821
- **Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis** *PLOS ONE*
Willis, S., Villalobos, V. M., Gevaert, O., Abramovitz, M., Williams, C., Sikic, B. I., Leyland-Jones, B.
2016; 11 (2)
- **The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells** *MOLECULAR ONCOLOGY*
Brozovic, A., Duran, G. E., Wang, Y. C., Francisco, E. B., Sikic, B. I.
2015; 9 (8): 1678-1693
- **Mechanisms of resistance to cabazitaxel.** *Molecular cancer therapeutics*
Duran, G. E., Wang, Y. C., Francisco, E. B., Rose, J. C., Martinez, F. J., Collier, J., Brassard, D., Vrignaud, P., Sikic, B. I.
2015; 14 (1): 193-201
- **Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers** *MOLECULAR ONCOLOGY*
Moisan, F., Francisco, E. B., Brozovic, A., Duran, G. E., Wang, Y. C., Chaturvedi, S., Seetharam, S., Snyder, L. A., Doshi, P., Sikic, B. I.
2014; 8 (7): 1231-1239
- **Clinical trial designs for testing biomarker-based personalized therapies** *CLINICAL TRIALS*
Lai, T. L., Lavori, P. W., Shih, M. I., Sikic, B. I.
2012; 9 (2): 141-154

- **Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance** *CLINICAL CANCER RESEARCH*
Chen, K. G., Sikic, B. I.
2012; 18 (7): 1863-1869
- **NFKBIA Deletion in Glioblastomas.** *NEW ENGLAND JOURNAL OF MEDICINE*
Bredel, M., Scholtens, D. M., Yadav, A. K., Alvarez, A. A., Renfrow, J. J., Chandler, J. P., Yu, I. L., Carro, M. S., Dai, F., Tagge, M. J., Ferrarese, R., Bredel, C., Phillips, et al
2011; 364 (7): 627-637
- **Expression and Silencing of the Microtubule-Associated Protein Tau in Breast Cancer Cells** *MOLECULAR CANCER THERAPEUTICS*
Spicakova, T., O'Brien, M. M., Duran, G. E., Sweet-Cordero, A., Sikic, B. I.
2010; 9 (11): 2970-2981
- **A Network Model of a Cooperative Genetic Landscape in Brain Tumors** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Bredel, M., Scholtens, D. M., Harsh, G. R., Bredel, C., Chandler, J. P., Renfrow, J. J., Yadav, A. K., Vogel, H., Scheck, A. C., Tibshirani, R., Sikic, B. I.
2009; 302 (3): 261-275
- **A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer** *CLINICAL CANCER RESEARCH*
Fischer, G., Kuo, T., Ramsey, M., Schwartz, E., Rouse, R., Cho, C. D., Halsey, J., Sikic, B. I.
2008; 14 (21): 7074-7079
- **Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias** *JOURNAL OF CLINICAL ONCOLOGY*
Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., Rowe, J. M., Goldstone, A. H., O'Dwyer, P. J., Paietta, E., Sikic, B. I.
2007; 25 (11): 1341-1349
- **Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines** *GENES CHROMOSOMES & CANCER*
Wang, Y. C., Juric, D., Francisco, B., Yu, R. X., Duran, G. E., Chen, G. K., Chen, X., Sikic, B. I.
2006; 45 (4): 365-374
- **Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies** *INVESTIGATIONAL NEW DRUGS*
Cho, C. D., Fisher, G. A., Halsey, J., Sikic, B. I.
2006; 24 (2): 117-123
- **Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappa B-mediated resistance to O-6-alkylating agents in human glioblastomas** *JOURNAL OF CLINICAL ONCOLOGY*
Bredel, M., Bredel, C., Juric, D., Duran, G. E., Yu, R. X., Harsh, G. R., Vogel, H., Recht, L. D., Scheck, A. C., Sikic, B. I.
2006; 24 (2): 274-287
- **Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Juric, D., Sale, S., Hromas, R. A., Yu, R., Wang, Y., Duran, G. E., Tibshirani, R., Einhorn, L. H., Sikic, B. I.
2005; 102 (49): 17763-17768
- **Genetic and epigenetic modeling of the origins of multidrug-resistant cells in a human sarcoma cell line** *CANCER RESEARCH*
Chen, K. G., Wang, Y. C., Schaner, M. E., Francisco, B., Duran, G. E., Juric, D., Huff, L. M., Padilla-Nash, H., Ried, T., Fojo, T., Sikic, B. I.
2005; 65 (20): 9388-9397
- **Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas** *CANCER RESEARCH*
Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., Recht, L. D., Sikic, B. I.
2005; 65 (19): 8679-8689
- **Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer** *40th Annual Meeting of the American-Society-of-Clinical-Oncology*
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., Ford, J. M., Fisher, G. A., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2005: 5613-19

- **High-resolution genome-wide mapping of genetic alterations in human glial brain tumors** *CANCER RESEARCH*
Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., Recht, L. D., Sikic, B. I.
2005; 65 (10): 4088-4096
- **Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes** *BLOOD*
Lacayo, N. J., Meshinchi, S., Kinnunen, P., Yu, R., Wang, Y., Stuber, C. M., Douglas, L., Wahab, R., Becton, D. L., Weinstein, H., Chang, M. N., Willman, C. L., Radich, et al
2004; 104 (9): 2646-2654
- **CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells** *MOLECULAR PHARMACOLOGY*
Chen, G. K., Sale, S., Tan, T., Ermoian, R. P., Sikic, B. I.
2004; 65 (4): 906-916
- **Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.** *Journal of experimental therapeutics & oncology*
Lacayo, N. J., Duran, G. E., Sikic, B. I.
2003; 3 (3): 127-135
- **Preferential expression of a mutant allele of the amplified MDR1 (ABC1) gene in drug-resistant variants of a human sarcoma** *GENES CHROMOSOMES & CANCER*
Chen, G. K., Lacayo, N. J., Duran, G. E., Wang, Y., Bangs, C. D., Rea, S., Kovacs, M., Cherry, A. M., Brown, J. M., Sikic, B. I.
2002; 34 (4): 372-383
- **MDR1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells** *BRITISH JOURNAL OF CANCER*
Chen, G. K., Duran, G. E., Mangili, A., Beketic-Oreskovic, L., Sikic, B.
2000; 83 (7): 892-898
- **Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant p-glycoprotein with deleted Phe(335)** *MOLECULAR PHARMACOLOGY*
Chen, G. K., Lacayo, N. J., Duran, G. E., Cohen, D., Sikic, B. I.
2000; 57 (4): 769-777
- **Modulation of multidrug resistance: A paradigm for translational clinical research** *ONCOLOGY-NEW YORK*
Sikic, B. I.
1999; 13 (5A): 183-187
- **Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein** *12th Bristol-Myers-Squibb Nagoya International Cancer Treatment Symposium*
Sikic, B. I., Fisher, G. A., Lum, B. L., Halsey, J., BEKETICORESKOVIC, L., Chen, G.
SPRINGER.1997: S13-S19
- **Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Chen, G., Duran, G. E., Steger, K. A., Lacayo, N. J., Jaffrezou, J. P., Dumontet, C., Sikic, B. I.
1997; 272 (9): 5974-5982
- **Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol)** *CANCER RESEARCH*
Dumontet, C., Duran, G. E., Steger, K. A., BEKETICORESKOVIC, L., Sikic, B. I.
1996; 56 (5): 1091-1097
- **DECREASED MUTATION-RATE FOR CELLULAR-RESISTANCE TO DOXORUBICIN AND SUPPRESSION OF MDR1 GENE ACTIVATION BY THE CYCLOSPORINE PSC-833** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
BEKETICORESKOVIC, L., Duran, G. E., Chen, G., Dumontet, C., Sikic, B. I.
1995; 87 (21): 1593-1602
- **The reversal of multidrug resistance.** *Cancer treatment and research*
Fisher, G. A., Lum, B. L., Sikic, B. I.
1995; 78: 45-70

- **PREVALENCE OF MULTIDRUG-RESISTANCE RELATED TO ACTIVATION OF THE MDR1 GENE IN HUMAN SARCOMA MUTANTS DERIVED BY SINGLE-STEP DOXORUBICIN SELECTION** *CANCER RESEARCH*
Chen, G., Jaffrezou, J. P., Fleming, W. H., Duran, G. E., Sikic, B. I.
1994; 54 (18): 4980-4987
- **MUTATION-RATES AND MECHANISMS OF RESISTANCE TO ETOPOSIDE DETERMINED FROM FLUCTUATION ANALYSIS** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Jaffrezou, J. P., Chen, G., Duran, G. E., Kuhl, J. S., Sikic, B. I.
1994; 86 (15): 1152-1158
- **PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE** *JOURNAL OF CLINICAL ONCOLOGY*
Bartlett, N. L., Lum, B. L., Fisher, G. A., BROPHY, N. A., EHSAN, M. N., Halsey, J., Sikic, B. I.
1994; 12 (4): 835-842
- **MODULATION OF MULTIDRUG-RESISTANCE - AT THE THRESHOLD** *JOURNAL OF CLINICAL ONCOLOGY*
Sikic, B. I.
1993; 11 (9): 1629-1635
- **PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE** *JOURNAL OF CLINICAL ONCOLOGY*
Yahanda, A. M., ADLER, K. M., Fisher, G. A., BROPHY, N. A., Halsey, J., Hardy, R. I., Gosland, M. P., Lum, B. L., Sikic, B. I.
1992; 10 (10): 1624-1634
- **ALTERATION OF ETOPOSIDE PHARMACOKINETICS AND PHARMACODYNAMICS BY CYCLOSPORINE IN A PHASE-I TRIAL TO MODULATE MULTIDRUG RESISTANCE** *JOURNAL OF CLINICAL ONCOLOGY*
Lum, B. L., Kaubisch, S., Yahanda, A. M., ADLER, K. M., JEW, L., EHSAN, M. N., BROPHY, N. A., Halsey, J., Gosland, M. P., Sikic, B. I.
1992; 10 (10): 1635-1642
- **MULTIDRUG RESISTANCE (MDR1) GENE-EXPRESSION IN ADULT ACUTE LEUKEMIAS - CORRELATIONS WITH TREATMENT OUTCOME AND INVITRO DRUG SENSITIVITY** *BLOOD*
Marie, J. P., Zittoun, R., Sikic, B. I.
1991; 78 (3): 586-592
- **MULTIDRUG (PLEIOTROPIC) RESISTANCE IN DOXORUBICIN-SELECTED VARIANTS OF THE HUMAN SARCOMA CELL-LINE MES-SA** *CANCER RESEARCH*
Harker, W. G., Sikic, B. I.
1985; 45 (9): 4091-4096
- **DISSOCIATION OF ANTITUMOR POTENCY FROM ANTHRACYCLINE CARDIOTOXICITY IN A DOXORUBICIN ANALOG** *SCIENCE*
Sikic, B. I., EHSAN, M. N., Harker, W. G., FRIEND, N. F., Brown, B. W., Newman, R. A., Hacker, M. P., ACTON, E. M.
1985; 228 (4707): 1544-1546
- **DEVELOPMENT AND CHARACTERIZATION OF A HUMAN SARCOMA CELL-LINE, MES-SA, SENSITIVE TO MULTIPLE-DRUGS** *CANCER RESEARCH*
Harker, W. G., MacKintosh, F. R., Sikic, B. I.
1983; 43 (10): 4943-4950
- **IMPROVED THERAPEUTIC INDEX OF BLEOMYCIN WHEN ADMINISTERED BY CONTINUOUS INFUSION IN MICE** *CANCER TREATMENT REPORTS*
Sikic, B. I., Collins, J. M., Mimnaugh, E. G., Gram, T. E.
1978; 62 (12): 2011-2017
- **QUANTIFICATION OF BLEOMYCIN PULMONARY TOXICITY IN MICE BY CHANGES IN LUNG HYDROXYPROLINE CONTENT AND MORPHOMETRIC HISTOPATHOLOGY** *CANCER RESEARCH*
Sikic, B. I., Young, D. M., Mimnaugh, E. G., Gram, T. E.
1978; 38 (3): 787-792
- **Editorial Expression of Concern: Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.** *British journal of cancer*
Duran, G. E., Wang, Y. C., Moisan, F., Francisco, E. B., Sikic, B. I.

2025

- **Carboplatin-induced upregulation of pan beta-tubulin and class III beta-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer.** *Cellular and molecular life sciences : CMLS*
Pernar Kovac, M., Tadic, V., Kralj, J., Duran, G. E., Stefanelli, A., Stupin Polancec, D., Dabelic, S., Bacic, N., Tomcic, M. T., Heffeter, P., Sikic, B. I., Brozovic, A.
2023; 80 (10): 294
- **A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.** *Cancer chemotherapy and pharmacology*
Marcelletti, J. F., Sikic, B. I.
2023
- **A Phase I Trial of the ABCB1 Inhibitor, Oral Valsopodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors.** *American journal of clinical oncology*
Fracasso, P. M., Fisher, G. A., Goodner, S. A., Beumer, J. H., Egorin, M. J., Fears, C. L., Wildi, J. D., Jones, G. J., Pearce, T. E., Sikic, B. I.
2023
- **Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.** *Journal for immunotherapy of cancer*
Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, et al
2022; 10 (8)
- **Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.** *Blood advances*
Ansell, S. M., Flinn, I., Taylor, M. H., Sikic, B. I., Brody, J., Nemunaitis, J., Feldman, A., Hawthorne, T. R., Rawls, T., Keler, T., Yellin, M. J.
2020; 4 (9): 1917–26
- **Genomic stability at the coding regions of the multidrug transporter gene ABCB1: insights into the development of alternative drug resistance mechanisms in human leukemia cells.** *Cancer drug resistance (Alhambra, Calif.)*
Chen, K. G., Duran, G. E., Mogul, M. J., Wang, Y. C., Ross, K. L., Jaffrezou, J., Huff, L. M., Johnson, K. R., Fojo, T., Lacayo, N. J., Sikic, B. I.
2020; 3: 959-979
- **The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance** *PLOS ONE*
Duran, G. E., Sikic, B. I.
2019; 14 (1)
- **Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia** *CYTOMETRY PART B-CLINICAL CYTOMETRY*
Marcelletti, J. F., Sikic, B. I., Cripe, L. D., Paietta, E.
2019; 96 (1): 57–66
- **Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe** *ONCOLOGIST*
Vrdoljak, E., Bodoky, G., Jassem, J., Popescu, R., Pirker, R., Cufer, T., Beslija, S., Eniu, A., Todorovic, V., Kopeckova, K., Kurteva, G., Tomasevic, Z., Sallaku, et al
2019; 24 (1): E30–E37
- **The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.** *PLoS one*
Duran, G. E., Sikic, B. I.
2019; 14 (1): e0210879
- **A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., Miles, D., Sikic, B. I., Wakelee, H. A.
2018; 82 (3): 541–50
- **A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies.** *Cancer chemotherapy and pharmacology*
Das, M., Padda, S. K., Frymoyer, A., Molina, J., Adjei, A., Lensing, J. L., Miles, D., Sikic, B. I., Wakelee, H. A.
2018

- **Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Duran, G. E., Derdau, V., Weitz, D., Philippe, N., Blankenstein, J., Atzrodt, J., Semiond, D., Gianolio, D. A., Mace, S., Sikic, B. I.
2018; 81 (6): 1095–1103
- **A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.**
Sikic, B. I., Lakhani, N. J., Patnaik, A., Shah, S., Chandana, S. R., Rasco, D. W., Colevas, A., O'Rourke, T. J., Papadopoulos, K. P., Fisher, G. A., Chao, M., Agoram, B., Chen, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas.**
Agoram, B., Wang, B., Sikic, B. I., Lakhani, N. J., Patnaik, A., Liu, J., Secreto, R., Chao, M., Takimoto, C. H. M.
AMER SOC CLINICAL ONCOLOGY.2018
- **Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results.**
Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A. M., Sikic, B. I., Rahma, O. E., Cho, D. C., Rizvi, N. A., Bitting, R. L., Starodub, A., Jimeno, A., Yellin, M., Rawls, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.** *Journal of clinical oncology*
Burriss, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., Sikic, B. I., Taylor, M. H., Northfelt, D. W., Carson, W. E., Hawthorne, T. R., Davis, T. A., Yellin, et al
2017: JCO2016701508-?
- **A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.** *Investigational new drugs*
Rosen, L. S., LoRusso, P., Ma, W. W., Goldman, J. W., Weise, A., Colevas, A. D., Adjei, A., Yazji, S., Shen, A., Johnston, S., Hsieh, H., Chan, I. T., Sikic, et al
2016; 34 (5): 604-613
- **Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement** *ONCOLOGIST*
Vrdoljak, E., Bodoky, G., Jassem, J., Popescu, R. A., Mardiak, J., Pirker, R., Cufer, T., Beslija, S., Eniu, A., Todorovic, V., Kubackova, K., Kurteva, G., Tomasevic, et al
2016; 21 (10): 1183-1190
- **A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers**
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors** *CLINICAL CANCER RESEARCH*
Smith, D. C., Eisenberg, P. D., Manikhas, G., Chugh, R., Gubens, M. A., Stagg, R. J., Kapoun, A. M., Xu, L., Dupont, J., Sikic, B.
2014; 20 (24): 6295-6303
- **Resistance to cabazitaxel is associated with ABCB1/P-glycoprotein activation, alterations in beta-tubulin content and dynamics, reduced BRCA1, and a mesenchymal phenotype in MCF-7 human breast cancer variants**
Duran, G. E., Wang, Y. C., Francisco, E., Martinez, F. J., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2014
- **Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies.**
Ansell, S. M., Northfelt, D. W., Flinn, I., Burriss, H. A., Dinner, S., Villalobos, V., Sikic, B. I., Taylor, M., Pijia, L., Hawthorne, T. R., Yellin, M., Keler, T., Davis, et al
AMER SOC CLINICAL ONCOLOGY.2014
- **Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pis) with solid tumors.**
Infante, J. R., Burriss, H. A., Ansell, S., Nemunaitis, J. J., Welss, G. R., Villalobos, V., Sikic, B. I., Taylor, M., Northfelt, D. W., Carson, W., Pijia, L., Hawthorne, T. R., Davis, et al

AMER SOC CLINICAL ONCOLOGY.2014

- **Identification of ovarian cancer driver genes by using module network integration of multi-omics data** *INTERFACE FOCUS*
Gevaert, O., Villalobos, V., Sikic, B. I., Plevritis, S. K.
2013; 3 (4)
- **Identification of ovarian cancer driver genes by using module network integration of multi-omics data.** *Interface focus*
Gevaert, O., Villalobos, V., Sikic, B. I., Plevritis, S. K.
2013; 3 (4): 20130013-?
- **Prognostic effect of EIF4EBP1 on ovarian cancer: A single gene biomarker for overall survival and platinum response.**
Villalobos, V., Wang, Y., Willis, S., Leyland-Jones, B., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2013
- **Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors** *INVESTIGATIONAL NEW DRUGS*
Kunz, P. L., He, A. R., Colevas, A. D., Pishvaian, M. J., Hwang, J. J., Clemens, P. L., Messina, M., Kaleta, R., Abrahao, F., Sikic, B. I., Marshall, J. L.
2012; 30 (6): 2364-2370
- **A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer** *INVESTIGATIONAL NEW DRUGS*
Cabebe, E. C., Fisher, G. A., Sikic, B. I.
2012; 30 (3): 1082-1087
- **Enhancement of paclitaxel and carboplatin therapy by CCL2 blockade in ovarian cancers**
Moisan, F., Francisco, E. B., Brozovic, A., Duran, G. E., Wang, Y. C., Seetharam, S., Snyder, L. A., Doshi, P., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2012
- **Comprehensive miRNA profiling of taxane-resistant human breast and ovarian cancer cell lines using the SmartChip real-time PCR system**
Duran, G. E., Wang, C. Y., Francisco, E., Wong, K., Robinson, N., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2012
- **Significance of MicroRNAs in determining taxane resistance in ovarian cancer**
Sultan, A., Kiet, T., Chan, J., Wang, Y., Duran, G., Francisco, B., Sikic, B.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2012: S131-S131
- **Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies** *INVESTIGATIONAL NEW DRUGS*
Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., Losa, R., Sierra, M. I., Sikic, B. I.
2011; 29 (5): 971-977
- **Integrated genomic analyses of ovarian carcinoma** *NATURE*
Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D. W., Dao, F., Dhir, R., Disaia, P., Gabra, H., Glenn, P., Godwin, A. K., GROSS, J., Hartmann, et al
2011; 474 (7353): 609-615
- **A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors**
Rosen, L., LoRusso, P., Ma, W., Goldman, J., Weise, A., Colevas, A., Adjei, A., Yazji, S., Shen, A., Johnston, S., Gates, M. R., Jones, C., Musib, et al
AMER ASSOC CANCER RESEARCH.2011
- **Comprehensive miRNA profiling of taxane-resistant human breast cancer variants using the SmartChip Real-Time PCR System**
Duran, G. E., Wang, C. Y., Francisco, E., Wong, K., Robinson, N., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2011
- **Phase I Study of Valspodar (PSC-833) With Mitoxantrone and Etoposide in Refractory and Relapsed Pediatric Acute Leukemia: A Report From the Children's Oncology Group** *PEDIATRIC BLOOD & CANCER*
O'Brien, M. M., Lacayo, N. J., Lum, B. L., Kshirsagar, S., Buck, S., Ravindranath, Y., Bernstein, M., Weinstein, H., Chang, M. N., Arceci, R. J., Sikic, B. I., Dahl, G. V.
2010; 54 (5): 694-702
- **Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors** *ANNALS OF ONCOLOGY*

Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., Miceli, R., Ullrich, S. J., Fisher, G. A., Tolcher, A. W.
2010; 21 (2): 376-381

- **A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia** *LEUKEMIA RESEARCH*
Lancet, J. E., Baer, M. R., Duran, G. E., List, A. F., Fielding, R., Marcelletti, J. F., Multani, P. S., Sikic, B. I.
2009; 33 (8): 1055-1061
- **Monosomy of Chromosome 10 Associated With Dysregulation of Epidermal Growth Factor Signaling in Glioblastomas** *JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION*
Yadav, A. K., Renfrow, J. J., Scholtens, D. M., Xie, H., Duran, G. E., Bredel, C., Vogel, H., Chandler, J. P., Chakravarti, A., Robe, P. A., Das, S., Scheck, A. C., Kessler, et al
2009; 302 (3): 276-289
- **Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia** *LEUKEMIA RESEARCH*
Marcelletti, J. F., Multani, P. S., Lancet, J. E., Baer, M. R., Sikic, B. I.
2009; 33 (6): 769-774
- **The expression of activator protein 2 (AP-2) transcription factors in MDR1(+) and MDR1(-) taxane resistant human breast carcinoma variants.**
Rose, J., Duran, G., Sikic, B.
AMER ASSOC CANCER RESEARCH.2009
- **A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors**
Rosen, L. S., Galatin, P., Fehling, J. M., Laux, I., Dinolfo, M., Frye, J., Laird, D., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2008
- **Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer**
Cabebe, E. C., Kuo, T., Koong, A., Welton, M., Shelton, A., Kunz, P. L., Ford, J. M., Sikic, B. I., KAISER, H. L., Rogers, J., Fisher, G. A.
AMER SOC CLINICAL ONCOLOGY.2008
- **An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer**
Kuo, T., Cabebe, E. C., Koong, A., NORTON, J. A., Kunz, P. L., Ford, J. M., KAISER, H. L., Rogers, J., Sikic, B. I., Fisher, G. A.
AMER SOC CLINICAL ONCOLOGY.2008
- **Analysis of phase II studies on targeted agents and subsequent phase III trials: What are the predictors for success?** *JOURNAL OF CLINICAL ONCOLOGY*
Chan, J. K., Ueda, S. M., Sugiyama, V. E., Stave, C. D., Shin, J. Y., Monk, B. J., Sikic, B. I., Osann, K., Kapp, D. S.
2008; 26 (9): 1511-1518
- **A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally daily to patients with advanced solid malignancies (ASM)**
Molina, J., Wakelee, H. A., Fehling, J. M., Lensingi, J. L., Calcagni, J., Funke, R. F., Miles, D., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2007: 3508S-3509S
- **A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.**
Sikic, B. I., Wakelee, H. A., Von Mehren, M., Lewis, N. L., Plummer, E., Calvert, A., Fox, N., Kumm, E. A., Jones, S. F., Burris, H. A.
AMER ASSOC CANCER RESEARCH.2007: 3454S-3455S
- **Phase I/II study of the P-glycoprotein (Pgp) inhibitor zosuquidar administered by continuous infusion (CIV) with daunorubicin (DNR) and cytarabine (ARA-C) as primary therapy in older patients with Pgp-positive acute myeloid leukemia (AML)**
Lancet, J. E., Gotlib, J., Wetzler, M., Luger, S., Cripe, L. D., Tallman, M. S., Gojo, I., Mulford, D., Baer, M. R., List, A. F., Multani, P. S., Sikic, B. I.
AMER SOC HEMATOLOGY.2007: 94A-95A
- **Predictors for success in a phase III trial - an analysis of 315 phase II chemotherapy trials for advanced cancers**
Ueda, S. M., Kapp, D. S., Sugiyama, V. E., Stave, C., Shin, J. Y., Monk, B. J., Sikic, B. I., Osann, K., Chan, J. K.
ACADEMIC PRESS INC ELSEVIER SCIENCE.2007: 362-63

- **Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors.** *Methods in molecular biology (Clifton, N.J.)*
Juric, D., Bredel, C., Sikic, B. I., Bredel, M.
2007; 377: 187-202
- **Gene expression profiling predicts outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421.** *48th Annual Meeting of the American-Society-of-Hematology*
Lacayo, N. J., O'Brien, M., Jain, S., Meshinchi, S., Yu, R., Juric, D., Chang, M. N., Tebshirani, R., Ravindranath, Y., Weinstein, H. J., Sikic, B. I., Van Houten Dahl, G.
AMER SOC HEMATOLOGY.2006: 542A-542A
- **Phase I/II pharmacodynamic study of the P-glycoprotein (Pgp) inhibitor zosuquidar administered by continuous infusion (CIV) with daunorubicin (DNR) and cytarabine (ARA-C) as primary therapy in older patients with acute myeloid leukemia (AML).**
Lancet, J., Baer, M. R., Cripe, L. D., List, A. F., Marcelletti, J. F., Multani, P. S., Sikic, B. I.
AMER SOC HEMATOLOGY.2006: 129A
- **Differential gene expression patterns and interaction networks in BCR/ABL positive and negative adult acute lymphoblastic leukemias.** *48th Annual Meeting of the American-Society-of-Hematology*
Juric, D., Lacayo, N. J., Ramsey, M. C., Racevskis, J., Wiernik, P. H., Rowe, J. M., Goldstone, A. H., O'Dwyer, P. J., Paietta, E., Sikic, B. I.
AMER SOC HEMATOLOGY.2006: 520A-520A
- **A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A trial of the eastern cooperative oncology group CANCER INVESTIGATION**
Carlson, R. W., O'Neill, A. M., Goldstein, L. J., Sikic, B. I., Abramson, N., Stewart, J. A., Davidson, N. E., Wood, W. C.
2006; 24 (7): 677-681
- **A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a novel spectrum selective kinase inhibitor, administered orally to patients with advanced solid malignancies (ASM)**
Sikic, B. I., Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., Dugay, J. D., Hanson, L. J., Reid, J. M., Piens, J. R.
PERGAMON-ELSEVIER SCIENCE LTD.2006: 106-7
- **A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM).** *42nd Annual Meeting of the American-Society-of-Clinical-Oncology*
Wakelee, H. A., Adjei, A. A., Halsey, J., Lensing, J. L., Dugay, J. D., Hanson, L. J., Reid, J. M., Piens, J. R., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2006: 131S-131S
- **Multidrug resistance and stem cells in acute myeloid leukemia** *CLINICAL CANCER RESEARCH*
Sikic, B. I.
2006; 12 (11): 3231-3232
- **Impaired taxane- and epothilone-driven tubulin polymerization in a non-MDR1 taxane- resistant MCF-7 breast cancer variant with reduced MAP4 and elevated MAP Tau content**
Duran, G. E., Jordan, M., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2006
- **TNFAIP3/A20 as a potential regulator of NF-kappa B-mediated resistance to O-6-alkylating chemotherapy in glioblastoma multiforme**
Bredel, M., Bredel, C., Juric, D., Duran, G., Yu, R. X., Harsh, G. R., Vogel, H., Recht, L. D., Scheck, A. C., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2006
- **Gene-dosage effects in the human glioma transcriptome and their potential biological impact based on in silico interactome mapping**
Bredel, M., Juric, D., Bredel, C., Harsh, G. R., Vogel, H., Recht, L. D., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2006
- **Gene copy number alterations and differential gene expression in the acquired resistance of ovarian cancer cells to taxanes**
Juric, D., Wang, Y. C., Yu, R. X., Duran, G. E., Francisco, E., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2006
- **Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein** *LEUKEMIA*
DiMartino, J. F., Lacayo, N. J., Varadi, M., Li, L., Saraiya, C., Ravindranath, Y., Yu, R., Sikic, B., Raimondi, S. C., Dahl, G.
2006; 20 (3): 426-432

- **Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421** *BLOOD*
Becton, D., Dahl, G. V., Ravindranath, Y., Chang, M. N., Behm, F. G., Raimondi, S. C., Head, D. R., Stine, K. C., Lacayo, N. J., Sikic, B. I., Arceci, R. J., Weinstein, H.
2006; 107 (4): 1315-1324
- **A phase 1 dose-escalation and pharmacokinetic (PK) study of a novel spectrum-selective kinase inhibitor (SSKI), XL647, in patients with advanced solid malignancies.** *17th EORTC/AACR/NCI International Conference on Molecular Targets and Cancer Therapeutics*
Wakelee, H., Adjei, A. A., Halsey, J., Lensing, J., Dugay, J., Hanson, L., Reid, J., Hutchison, S., Piens, J., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2005: 9029S-9029S
- **A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance** *ANNALS OF ONCOLOGY*
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C. D., Sikic, B. I.
2005; 16 (12): 1968-1973
- **Gene expression profiling and FLT3 status correlate with outcome in de novo acute myeloid leukemia (AML) with normal karyotype: Results of children's oncology group (COG) study POG #9421.** *47th Annual Meeting of the American-Society-of-Hematology*
Lacayo, N., Meshinchi, S., Raimondi, S., Saraiya, C., O'Brien, M., Yu, R., Juric, D., Chang, M., Willman, C., Tibshirani, R., Ravindranath, Y., Sikic, B., Weinstein, et al
AMER SOC HEMATOLOGY.2005: 667A-667A
- **Array CGH discovers novel genomic signatures in de novo acute myeloid leukemia (AML): Results of children's oncology group (COG) study POG #9421**
Kuo, D. J., Lacayo, N. J., Hoang, D., Juric, D., Raimondi, S. C., Chen, D., Chang, M. N., Ravindranath, Y., Weinstein, H. J., Sikic, B. I., Dahl, G. V.
AMER SOC HEMATOLOGY.2005: 777A
- **A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., Holmlund, J. T., Kwoh, T. J., DORR, F. A., Sikic, B. I.
SPRINGER.2005: 467-77
- **Activity of novel cytotoxic agents in lung cancer: Etoposides and topoisomerase I inhibitors** *CLINICAL LUNG CANCER*
Wakelee, H. A., Sikic, B. I.
2005; 7: S6-S12
- **A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer** *INVESTIGATIONAL NEW DRUGS*
Chi, K. N., Chia, S. K., Dixon, R., Newman, M. J., Wachter, V. J., Sikic, B., Gelmon, K. A.
2005; 23 (4): 311-315
- **A phase I trial of oblimersen and gemcitabine in refractory and advanced malignancies** *41st Annual Meeting of the American-Society-of-Clinical-Oncology*
Fisher, G., Advani, R., Wakelee, H., Jacobs, C., Gladysheva, K., Fitzgerald, A. M., Sikic, B.
AMER SOC CLINICAL ONCOLOGY.2005: 234S-234S
- **A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies** *41st Annual Meeting of the American-Society-of-Clinical-Oncology*
Wakelee, H., Adjei, A. A., Keer, H., Halsey, J., Hanson, L., Reid, J., Hutchison, S., Piens, J., Lacy, S., Sikic, B. I.
AMER SOC CLINICAL ONCOLOGY.2005: 227S-227S
- **Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA** *JOURNAL OF MOLECULAR DIAGNOSTICS*
Bredel, M., Bredel, C., Juric, D., Kim, Y., Vogel, H., Harsh, G. R., Recht, L. D., Pollack, J. R., Sikic, B. I.
2005; 7 (2): 171-182
- **Osteonectin/SPARC is epigenetically silenced in AML with MLL gene rearrangements and selectively inhibits the growth of MLL rearranged cell lines** *46th Annual Meeting of the American-Society-of-Hematology*
DiMartino, J. F., Lacayo, N. J., Varadi, M., Ravindranath, Y., Yu, R., Sikic, B., Raimondi, S. C., Dahl, G. V.
AMER SOC HEMATOLOGY.2004: 314A-314A
- **FLT3 mutations determine the clinical outcome in children with de novo acute myelogenous leukemia (AML) and normal karyotype: Pediatric Oncology Group (POG) study # 9421.**

- Lacayo, N. J., Meshinchi, S., Raimondi, S. C., Kuo, D. J., Yu, R., Chang, M. N., Willman, C. L., Tibshirani, R., Ravindranath, Y., Sikic, B. I., Weinstein, H., Dahl, G. V.
AMER SOC HEMATOLOGY.2004: 165A
- **Gene expression profiling identifies genes associated with in vitro resistance to daunorubicin and cytarabine in children with de novo acute myelogenous leukemia (AML) from the Pediatric Oncology Group (POG) study # 9421**
Kuo, D. J., Lacayo, N. J., Buck, S., Yu, R., Saraiya, C., Douglas, L., Weinstein, H., Chang, M., Willman, C. L., Tibshirani, R., Dahl, G. V., Sikic, B., Ravindranath, et al
AMER SOC HEMATOLOGY.2004: 320A
 - **A method for detecting and correcting feature misidentification on expression microarrays** *BMC GENOMICS*
Tu, I. P., Schaner, M., Diehn, M., Sikic, B. I., Brown, P. O., Botstein, D., Fero, M. J.
2004; 5
 - **Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.** *Bulletin du cancer*
Dumontet, C., Jaffrezou, J., Tsuchiya, E., Duran, G. E., Chen, G., Derry, W. B., Wilson, L., Jordan, M. A., Sikic, B. I.
2004; 91 (5): E81-112
 - **Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)** *JOURNAL OF CLINICAL ONCOLOGY*
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., Dugan, K., Lum, B., Chin, D. L., Dewald, G., Paietta, E., Bennett, J. M., Rowe, et al
2004; 22 (6): 1078-1086
 - **Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours?** *LANCET ONCOLOGY*
Bredel, M., Bredel, C., Sikic, B. I.
2004; 5 (2): 89-100
 - **A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma** *36th Annual Meeting of the American-Society-of-Clinical-Oncology*
Advani, R., Peethambaram, P., Lum, B. L., Fisher, G. A., Hartmann, L., Long, H. J., Halsey, J., Holmlund, J. T., Dorr, A., Sikic, B. I.
JOHN WILEY & SONS INC.2004: 321-26
 - **A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.** *AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics*
Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., Rouse, R. V., Advani, R. H., Wakelee, H. A., Lum, B. L., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2003: 6103S-6103S
 - **Gene expression profiling (GEP) in de novo pediatric acute myeloid leukemia (AML) patients reveals a robust expression signature that correlates with inv(16) and t(16;16).**
Lacayo, N., Kinnunen, P., Raimondi, S. C., Yu, R., Wahab, R., Stuber, C., Douglas, L., Chang, M., Willman, C. L., Ravindranath, Y., Weinstein, H., Becton, D., Behm, et al
AMER SOC HEMATOLOGY.2003: 365A
 - **Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies** *CLINICAL CANCER RESEARCH*
Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., Cohen, M., Gollerkeri, A., Sikic, B. I.
2003; 9 (14): 5187-5194
 - **Gene expression patterns in ovarian carcinomas** *MOLECULAR BIOLOGY OF THE CELL*
Schaner, M. E., Ross, D. T., Ciaravino, G., Sorlie, T., Troyanskaya, O., Diehn, M., Wang, Y. C., Duran, G. E., Sikic, T. L., Caldeira, S., Skomedal, H., Tu, I. P., Hernandez-Boussard, et al
2003; 14 (11): 4376-4386
 - **Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer** *BREAST CANCER RESEARCH AND TREATMENT*
Hartman, A. R., Grekowicz, A., Lum, B. L., Carlson, R. W., Schurman, C., Sikic, B. I., Shapiro, R., Stockdale, F. E.
2003; 82 (1): 61-69
 - **Protein expression study of ovarian surface epithelial neoplasms using tissue microarray analysis: Emergence of a clear cell signature profile** *92nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*

- Balzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., Sikic, B., Longacre, T.
NATURE PUBLISHING GROUP.2003: 181A–181A
- **Protein expression study of ovarian surface epithelial neoplasms using tissue microarray analysis: Emergence of a clear cell signature profile** *92nd Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology*
Balzer, B., Schaner, M., Ross, D., Montgomery, K., Teng, N., Sikic, B., Longacre, T.
NATURE PUBLISHING GROUP.2003: 181A–181A
 - **Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography** *JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES*
Chin, D. L., Lum, B. L., Sikic, B. I.
2002; 779 (2): 259-269
 - **A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies** *14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics*
Fisher, G. A., Cho, C. D., Halsey, J. Z., Advani, R. H., Yuen, A. R., Lum, B. L., Sikic, B. I.
ELSEVIER SCI LTD.2002: S63–S63
 - **A phase I pharmacokinetic study of ONT-093 in combination with paclitaxel in patients with advanced cancer** *14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics*
Chi, K. N., Chia, S. K., Sikic, B., Dixon, R., Newman, M., Wachter, V. J., Toyonaga, B., Hoth, D., Gelmon, K. A.
ELSEVIER SCI LTD.2002: S156–S156
 - **Re: Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Sale, S., Oefner, P. J., Sikic, B. I.
2002; 94 (10): 776-777
 - **Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia** *LEUKEMIA*
Lacayo, N. J., Lum, B. L., Becton, D. L., Weinstein, H., Ravindranath, Y., Chang, M. N., Bomgaars, L., Lauer, S. J., Sikic, B. I., Dahl, G. V.
2002; 16 (5): 920-927
 - **The effect of oral valspodar (psc 833), a modulator of multidrug resistance, on the pharmacokinetics of liposomal doxorubicin.**
Lum, B. L., Chin, D. L., Cho, C. D., Advani, R., Fisher, G. A., Halsey, J., Sikic, B. I.
NATURE PUBLISHING GROUP.2002: P48–P48
 - **Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers** *MOLECULAR CANCER THERAPEUTICS*
Sale, S., Sung, R., Shen, P. D., Yu, K., Wang, Y., Duran, G. E., Kim, J. H., Fojo, T., Oefner, P. J., Sikic, B. I.
2002; 1 (3): 215-225
 - **Motexafin gadolinium: A redox active drug that enhances the efficacy of bleomycin and doxorubicin** *CLINICAL CANCER RESEARCH*
MILLER, R. A., Woodburn, K. W., Fan, Q., Lee, I., Miles, D., Duran, G., Sikic, B., Magda, D.
2001; 7 (10): 3215-3221
 - **A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance** *34th Annual Meeting of the American-Society-of-Clinical-Oncology*
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., Litchman, M., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.2001: 1221–29
 - **Dominant effector genetics in mammalian cells** *NATURE GENETICS*
Xu, X., Leo, C., Jang, Y. J., Chan, E., Padilla, D., Huang, B. C., Lin, T., Gururaja, T., Hitoshi, Y., Lorens, J. B., Anderson, D. C., Sikic, B., Luo, et al
2001; 27 (1): 23-29
 - **Clinical studies of antisense therapy in cancer** *FRONTIERS IN BIOSCIENCE*
Yuen, A. R., Sikic, B. I.
2000; 5: D588-D593
 - **Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
Dahl, G. V., Lacayo, N. J., Brophy, N., Dunussi-Joannopoulos, K., Weinstein, H. J., Chang, M. R., Sikic, B. I., Arceci, R. J.

2000; 18 (9): 1867-1875

- **Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin** *ANTI-CANCER DRUGS*
Cufer, T., Pfeifer, M., Vrhovec, I., Frangez, R., Kosec, M., Mrhar, A., Grabnar, I., Golouh, R., Vogric, S., Sikic, B. I.
2000; 11 (4): 303-309
- **Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Lum, B. L., Kaubisch, S., Fisher, G. A., Brown, B. W., Sikic, B. I.
2000; 45 (4): 305-311
- **Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs MEC: Randomized phase III trial (E2995).**
Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, K., Lee, S. J., Lum, B., Sikic, B. I., Paietta, E., Bennett, J., Rowe, J. M.
AMER SOC HEMATOLOGY.1999: 383A–383A
- **Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer** *CLINICAL CANCER RESEARCH*
Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., Kwoh, T. J., Dorr, A., Sikic, B. I.
1999; 5 (11): 3357-3363
- **Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death** *JOURNAL OF CLINICAL ONCOLOGY*
Dumontet, C., Sikic, B. I.
1999; 17 (3): 1061-1070
- **Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC833 (Valspodar)** *39th Annual Meeting of the American-Society-of-Hematology*
Advani, R., Saba, H. I., Tallman, M. S., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., Paietta, E., Litchman, M., Sikic, et al
AMER SOC HEMATOLOGY.1999: 787–95
- **Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia - An Eastern Cooperative Oncology Group Pilot Study** *38th Annual Meeting of the American-Society-of-Hematology*
Tallman, M. S., Lee, S., Sikic, B. I., Paietta, E., Wiernik, P. H., Bennett, J. M., Rowe, J. M.
JOHN WILEY & SONS INC.1999: 358–67
- **Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC)** *3rd International Symposium on Drug Resistance in Leukemia and Lymphoma*
Advani, R., Visani, G., Milligan, D., Saba, H., Tallman, M., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., Paietta, et al
KLUWER ACADEMIC/PLENUM PUBL.1999: 47–56
- **New approaches in cancer treatment** *Central European Oncology Congress*
Sikic, B. I.
OXFORD UNIV PRESS.1999: 149–153
- **Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells** *JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES*
Washington, C. B., Duran, G. E., Man, M. C., Sikic, B. I., Blaschke, T. F.
1998; 19 (3): 203-209
- **Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Cufer, T., Vrhovec, I., Pfeifer, M., Skrk, J., Borstnar, S., Sikic, B. I.
1998; 41 (6): 517-521
- **Pharmacologic approaches to reversing multidrug resistance** *SEMINARS IN HEMATOLOGY*
Sikic, B. I.
1997; 34 (4): 40-47

- **Validation of a limited sampling model to determine etoposide area under the curve** *PHARMACOTHERAPY*
Lum, B. L., LANE, K. J., Synold, T. W., Goram, A., Charnick, S. B., Sikic, B. I.
1997; 17 (5): 887-890
- **Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine** *ANNALS OF ONCOLOGY*
Advani, R., Warnke, R., Sikic, B. I., Horning, S.
1997; 8 (6): 601-603
- **Spontaneous overexpression of the long form of the bcl-X protein in a highly resistant P388 leukaemia** *BRITISH JOURNAL OF CANCER*
Kuhl, J. S., Krajewski, S., Duran, G. E., Reed, J. C., Sikic, B. I.
1997; 75 (2): 268-274
- **Differential single- versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Duran, G. E., Lau, D. H., Lewis, A. D., Kuhl, J. S., Bammler, T. K., Sikic, B. I.
1996; 38 (3): 210-216
- **Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors: Consensus recommendations** *CANCER RESEARCH*
Beck, W. T., Grogan, T. M., Willman, C. L., CORDONCARDO, C., Parham, D. M., Kuttesch, J. F., Andreeff, M., Bates, S. E., Berard, C. W., Boyett, J. M., BROPHY, N. A., Broxterman, H. J., Chan, et al
1996; 56 (13): 3010-3020
- **Pharmacological considerations in the modulation of multidrug resistance** *EUROPEAN JOURNAL OF CANCER*
Fisher, G. A., Lum, B. L., Hausdorff, J., Sikic, B. I.
1996; 32A (6): 1082-1088
- **Doxorubicin selection for MDR1/P-glycoprotein reduces swelling-activated K⁺ and Cl⁻ currents in MES-SA cells** *AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY*
Luckie, D. B., Krouse, M. E., Law, T. C., Sikic, B. I., Wine, J. J.
1996; 270 (4): C1029-C1036
- **Neural network (NN) and linear regression limited sampling models (LSM) for etoposide (E) AUC determinations.**
Lum, B. L., Synold, T. W., Lane, K., Charnick, S. B., Sikic, B. I.
NATURE PUBLISHING GROUP:1996: OIA2-OIA2
- **Differential expression of tubulin isotypes during the cell cycle** *CELL MOTILITY AND THE CYTOSKELETON*
Dumontet, C., Duran, G. E., Steger, K. A., Murphy, G. L., Sussman, H. H., Sikic, B. I.
1996; 35 (1): 49-58
- **Effect of different mathematical methods on etoposide area under the curve estimations and pharmacodynamic: Response predictions** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
McCauley, D. L., Lum, B. L., Sikic, B. I.
1996; 37 (3): 286-288
- **GLUTATHIONE-S-TRANSFERASE-PI, GLUTATHIONE-S-TRANSFERASE-ALPHA, GLUTATHIONE-S-TRANSFERASE-MU AND GLUTATHIONE-S-TRANSFERASE-MDR1 MESSENGER-RNA EXPRESSION IN NORMAL LYMPHOCYTES AND CHRONIC LYMPHOCYTIC-LEUKEMIA** *LEUKEMIA*
Marie, J. P., Simonin, G., Legrand, O., Delmer, A., Faussat, A. M., Lewis, A. D., Sikic, B. I., Zittoun, R.
1995; 9 (10): 1742-1747
- **CYCLOSPORINE-A INCREASES SERUM CORTISOL-LEVELS IN RABBITS** *ANTI-CANCER DRUGS*
Cufer, T., Vrhovec, I., Skrk, J., Pfeifer, M., Pajk, B., Zakotnik, B., Filipic, B., Rode, B., Sikic, B. I.
1995; 6 (4): 615-618
- **INHIBITION OF LYSOSOMAL ACID SPHINGOMYELINASE BY AGENTS WHICH REVERSE MULTIDRUG-RESISTANCE** *BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH*
Jaffrezou, J. P., Chen, G., Duran, G. E., Muller, C., Bordier, C., Laurent, G., Sikic, B. I., Levade, T.
1995; 1266 (1): 1-8
- **Drug resistance in clinical oncology and hematology. Introduction.** *Hematology/oncology clinics of North America*
Fisher, G. A., Sikic, B. I.

1995; 9 (2): xi-xii

- **CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE** *HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA*
Fisher, G. A., Sikic, B. I.
1995; 9 (2): 363-382
- **Novel mechanism of resistance to paclitaxel (Taxol(R)) in human K562 leukemia cells by combined selection with PSC 833** *ONCOLOGY RESEARCH*
Jaffrezou, J. P., Dumontet, C., Derry, W. B., Duran, G., Chen, G., Tsuchiya, E., Wilson, L., Jordan, M. A., Sikic, B. I.
1995; 7 (10-11): 517-527
- **EVIDENCE FOR TRANSCRIPTIONAL CONTROL OF HUMAN MDR1 GENE-EXPRESSION BY VERAPAMIL IN MULTIDRUG-RESISTANT LEUKEMIC-CELLS** *MOLECULAR PHARMACOLOGY*
Muller, C., Goubin, F., Ferrandis, E., CORNILSCHARWITZ, I., Bailly, J. D., Bordier, C., Benard, J., Sikic, B. I., Laurent, G.
1995; 47 (1): 51-56
- **ANALYSIS OF INTRACELLULAR RETENTION OF MORPHOLINYL ANTHRACYCLINES IN MULTIDRUG-RESISTANT CANCER-CELLS BY INTERACTIVE LASER CYTOMETRY** *INTERNATIONAL JOURNAL OF ONCOLOGY*
Lau, D. H., Duran, G. E., Sikic, B. I.
1994; 5 (6): 1273-1277
- **RESISTANCE TO PACLITAXEL TAXOL(R) IN KPTA5 VARIANTS OF K562 CELLS IS ASSOCIATED WITH THE OVEREXPRESSION OF 5-BETA-ISOTYPE OF TUBULIN**
DUMONTET, C., JAFFREZOU, J. P., DURAN, G., JORDAN, M. A., WILSON, L., SIKIC, B.
W B SAUNDERS CO.1994: A603
- **MULTIDRUG-RESISTANCE IN LYMPHOMAS** *JOURNAL OF CLINICAL ONCOLOGY*
Yuen, A. R., Sikic, B. I.
1994; 12 (11): 2453-2459
- **VOLUME-ACTIVATED CHLORIDE CURRENT IS NOT RELATED TO P-GLYCOPROTEIN OVEREXPRESSION** *CANCER RESEARCH*
Dong, Y. J., Chen, G., Duran, G. E., Kouyama, K., Chao, A. C., Sikic, B. I., Gollapudi, S. V., Gupta, S., Gardner, P.
1994; 54 (19): 5029-5032
- **METABOLIC CONVERSION OF METHOXYMORPHOLINYL DOXORUBICIN - FROM A DNA STRAND BREAKER TO A DNA CROSS-LINKER** *BRITISH JOURNAL OF CANCER*
Lau, D. H., Duran, G. E., Lewis, A. D., Sikic, B. I.
1994; 70 (1): 79-84
- **MDR1 GENE-EXPRESSION IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIAS AND LYMPHOMAS - A CRITICAL-EVALUATION BY 4 TECHNIQUES** *LEUKEMIA*
BROPHY, N. A., Marie, J. P., ROJAS, V. A., Warnke, R. A., MCFALL, P. J., Smith, S. D., Sikic, B. I.
1994; 8 (2): 327-335
- **PHARMACODYNAMICS (PD) OF DOXORUBICIN (DOX) WITH CYCLOSPORINE (CSA) AS A MODULATOR OF DRUG-RESISTANCE**
LUM, B. L., BARTLETT, N. L., FISHER, G. A., BROPHY, N. A., EHSAN, M., HALSEY, J., SIKIC, B. I.
MOSBY-YEAR BOOK INC.1994: 210
- **CYCLOSPORINE A AND CYCLOSPORINE SDZ PSC 833 ENHANCE ANTI-CD5 RICIN A-CHAIN IMMUNOTOXINS IN HUMAN LEUKEMIC T-CELLS** *BLOOD*
Jaffrezou, J. P., Sikic, B. I., Laurent, G.
1994; 83 (2): 482-489
- **Clinical reversal of multidrug resistance.** *Cancer treatment and research*
Sikic, B. I., Fisher, G. A., Lum, B. L., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., Halsey, J.
1994; 73: 149-165
- **REVERSAL OF MULTIDRUG-RESISTANCE TO CANCER-CHEMOTHERAPY** *2nd national conference on new oncologic agents : Practical applications*
LEYLANDJONES, B., Dalton, W., Fisher, G. A., Sikic, B. I.
WILEY-LISS.1993: 3484-88

- **CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS** *2nd national conference on new oncologic agents : Practical applications*
Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., Kaubisch, S., Halsey, J., Sikic, B. I.
WILEY-LISS.1993: 3502-14
- **EFFECTS OF THE METHOXYMORPHOLINO DERIVATIVE OF DOXORUBICIN AND ITS BIOACTIVATED FORM VERSUS DOXORUBICIN ON HUMAN LEUKEMIA AND LYMPHOMA CELL-LINES AND NORMAL BONE-MARROW** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Kuhl, J. S., Duran, G. E., Chao, N. J., Sikic, B. I.
1993; 33 (1): 10-16
- **MOLECULAR TARGETS IN ONCOLOGY - IMPLICATIONS OF THE MULTIDRUG RESISTANCE GENE** *PHARMACOTHERAPY*
Lum, B. L., Gosland, M. P., Kaubisch, S., Sikic, B. I.
1993; 13 (2): 88-109
- **THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD** *INTERNATIONAL SYMP ON THE MECHANISM AND NEW APPROACH ON DRUG RESISTANCE OF CANCER CELLS*
Fisher, G. A., BROPHY, N. A., Yahanda, A. M., Adler, K. A., Lum, B. L., Bartlett, N. L., Halsey, J., Sikic, B. I.
ELSEVIER SCIENCE PUBL B V.1993: 255-266
- **CHARACTERIZATION OF COVALENT DNA-BINDING OF MORPHOLINO AND CYANOMORPHOLINO DERIVATIVES OF DOXORUBICIN** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Lau, D. H., Duran, G. E., Sikic, B. I.
1992; 84 (20): 1587-1592
- **USE OF ETOPOSIDE IN COMBINATION WITH CYCLOSPORINE FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC-CELLS FROM BONE-MARROW IN A MOUSE MODEL** *EXPERIMENTAL HEMATOLOGY*
Kuhl, J. S., Sikic, B. I., Blume, K. G., Chao, N. J.
1992; 20 (9): 1048-1054
- **ROLE OF CYTOCHROME-P-450 FROM THE HUMAN CYP3A GENE FAMILY IN THE POTENTIATION OF MORPHOLINO DOXORUBICIN BY HUMAN LIVER-MICROSOMES** *CANCER RESEARCH*
Lewis, A. D., Lau, D. H., Duran, G. E., Wolf, C. R., Sikic, B. I.
1992; 52 (16): 4379-4384
- **EXPRESSION OF MULTIDRUG RESISTANCE GENE MDR1 MESSENGER-RNA IN A SUBSET OF NORMAL BONE-MARROW CELLS** *BRITISH JOURNAL OF HAEMATOLOGY*
Marie, J. P., BROPHY, N. A., EHSAN, M. N., Aihara, Y., Mohamed, N. A., CORNBLEET, J., Chao, N. J., Sikic, B. I.
1992; 81 (2): 145-152
- **Use of etoposide in combination with cyclosporine for purging multidrug resistant leukemic cells from bone marrow in a mouse model.** *Progress in clinical and biological research*
Kühl, J. S., Sikic, B. I., Blume, K. G., Chao, N. J.
1992; 377: 25-34
- **COMBINED CHEMOTHERAPY AND RADIOTHERAPY FOR ADVANCED-STAGE CARCINOMAS OF THE CERVIX** *26TH ANNUAL SAN FRANCISCO CANCER SYMP*
Sikic, B. I.
KARGER.1992: 153-162
- **Purging multidrug resistant cells from bone marrow.** *Progress in clinical and biological research*
Chao, N. J., Aihara, M., Kühl, J. S., Sikic, B. I., Blume, K. G.
1992; 377: 13-23
- **SENSITIZATION OF DRUG-RESISTANT HUMAN OVARIAN-CANCER CELLS TO CYANOMORPHOLINO DOXORUBICIN (MRA-CN) BY MODULATION OF GLUTATHIONE METABOLISM** *7TH INTERNATIONAL CONF ON CHEMICAL MODIFIERS OF CANCER TREATMENT*
Lewis, A. D., Duran, G. E., Lau, D. H., Sikic, B. I.
ELSEVIER SCIENCE INC.1992: 821-24
- **MULTIFACTORIAL MECHANISMS ASSOCIATED WITH BROAD CROSS-RESISTANCE OF OVARIAN-CARCINOMA CELLS SELECTED BY CYANOMORPHOLINO DOXORUBICIN** *CANCER RESEARCH*
Lau, D. H., Lewis, A. D., EHSAN, M. N., Sikic, B. I.

1991; 51 (19): 5181-5187

- **LATE CONSOLIDATIVE RADIATION-THERAPY IN THE TREATMENT OF LIMITED-STAGE SMALL-CELL LUNG-CANCER** *CANCER*
Carlson, R. W., Sikic, B. I., Gandara, D. R., HENDRICKSON, C. G., WITTLINGER, P. S., Shields, J. A., Wong, P. P., WHITE, J. E., MEAKIN, C. J., MCWHIRTER, K. M., Lamborn, K. R., Phillips, T. L.
1991; 68 (5): 948-958
- **ANTICANCER DRUG DISCOVERY** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Sikic, B. I.
1991; 83 (11): 738-740
- **A COMBINED APPROACH FOR PURGING MULTIDRUG-RESISTANT LEUKEMIC-CELL LINES IN BONE-MARROW USING A MONOCLONAL-ANTIBODY AND CHEMOTHERAPY** *BLOOD*
Aihara, M., Aihara, Y., SCHMIDTWOLF, G., SCHMIDTWOLF, I., Sikic, B. I., Blume, K. G., Chao, N. J.
1991; 77 (9): 2079-2084
- **CISPLATIN NEPHROTOXICITY - DIETHYLDITHIOCARBAMATE, WR2721, OR JUST WATER - REPLY** *JOURNAL OF CLINICAL ONCOLOGY*
Jacobs, C., Sikic, B. I.
1991; 9 (4): 708-709
- **THE USE OF PROBENECID AS A CHEMOPROTECTOR AGAINST CISPLATIN NEPHROTOXICITY** *CANCER*
Jacobs, C., Kaubisch, S., Halsey, J., Lum, B. L., GOSLAND, M., Coleman, C. N., Sikic, B. I.
1991; 67 (6): 1518-1524
- **MODULATION OF ETOPOSIDE (VP-16) CYTOTOXICITY BY VERAPAMIL OR CYCLOSPORINE IN MULTIDRUG-RESISTANT HUMAN LEUKEMIC-CELL LINES AND NORMAL BONE-MARROW** *EXPERIMENTAL HEMATOLOGY*
Chao, N. J., Aihara, M., Blume, K. G., Sikic, B. I.
1990; 18 (11): 1193-1198
- **SUCCESSFUL TREATMENT OF METASTATIC THYMIC CARCINOMA WITH CISPLATIN, VINBLASTINE, BLEOMYCIN, AND ETOPOSIDE CHEMOTHERAPY** *CANCER*
Carlson, R. W., Dorfman, R. F., Sikic, B. I.
1990; 66 (10): 2092-2094
- **ASSESSMENT OF PURGING WITH MULTIDRUG RESISTANCE (MDR) MODULATORS AND VP-16 - RESULTS OF LONG-TERM MARROW CULTURE** *EXPERIMENTAL HEMATOLOGY*
Aihara, M., Sikic, B. I., Blume, K. G., Chao, N. J.
1990; 18 (8): 940-944
- **MODIFICATION OF CISPLATIN TOXICITY WITH DIETHYLDITHIOCARBAMATE** *JOURNAL OF CLINICAL ONCOLOGY*
Berry, J. M., Jacobs, C., Sikic, B., Halsey, J., Borch, R. F.
1990; 8 (9): 1585-1590
- **PARADOXICAL INCREASE IN DNA CROSS-LINKING IN A HUMAN OVARIAN-CARCINOMA CELL-LINE RESISTANT TO CYANOMORPHOLINO DOXORUBICIN** *CANCER RESEARCH*
Lau, D. H., Ross, K. L., Sikic, B. I.
1990; 50 (13): 4056-4060
- **DELIVERY OF A NORMAL INFANT FOLLOWING CISPLATIN, VINBLASTINE, AND BLEOMYCIN (PVB) CHEMOTHERAPY FOR MALIGNANT TERATOMA OF THE OVARY DURING PREGNANCY** *GYNECOLOGIC ONCOLOGY*
CHRISTMAN, J. E., Teng, N. N., LEBOVIC, G. S., Sikic, B. I.
1990; 37 (2): 292-295
- **PRELIMINARY-RESULTS OF CONCURRENT RADIOTHERAPY AND CHEMOTHERAPY IN ADVANCED CERVICAL-CARCINOMA - A PHASE I-II PROSPECTIVE INTERGROUP NCOG-RTOG STUDY** *GYNECOLOGIC ONCOLOGY*
John, M., Flam, M., Sikic, B., Rotman, M., Cooper, J., Malec, M., Hannigan, J., Phillips, T.
1990; 37 (1): 1-5
- **REVERSAL BY CEFOPERAZONE OF RESISTANCE TO ETOPOSIDE, DOXORUBICIN, AND VINBLASTINE IN MULTIDRUG RESISTANT HUMAN SARCOMA-CELLS** *CANCER RESEARCH*
Gosland, M. P., Lum, B. L., Sikic, B. I.

1989; 49 (24): 6901-6905

- **Antitumor antibiotics.** *Current opinion in oncology*
Sikic, B. I.
1989; 1 (2): 198-202
- **DETECTION OF CELL-AFFECTING AGENTS WITH A SILICON BIOSENSOR** *SCIENCE*
Parce, J. W., Owicki, J. C., KERCSO, K. M., Sigal, G. B., Wada, H. G., MUIR, V. C., BOUSSE, L. J., Ross, K. L., Sikic, B. I., McConnell, H. M.
1989; 246 (4927): 243-247
- **ASSOCIATION OF DNA CROSS-LINKING WITH POTENTIATION OF THE MORPHOLINO DERIVATIVE OF DOXORUBICIN BY HUMAN-LIVER MICROSOMES** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Lau, D. H., Lewis, A. D., Sikic, B. I.
1989; 81 (13): 1034-1038
- **DNA CROSS-LINKING AND CYTO-TOXICITY OF THE ALKYLATING CYANOMORPHOLINO DERIVATIVE OF DOXORUBICIN IN MULTIDRUG-RESISTANT CELLS** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Scudder, S. A., Brown, J. M., Sikic, B. I.
1988; 80 (16): 1294-1298
- **CHARACTERIZATION AND IMMUNOASSAY OF HUMAN TUMOR-ASSOCIATED GALACTOSYLTRANSFERASE ISOENZYME-II** *CANCER RESEARCH*
Uemura, M., Winant, R. C., Sikic, B. I., Brandt, A. E.
1988; 48 (18): 5325-5334
- **ADVANCED EPITHELIAL OVARIAN-CANCER - SALVAGE WHOLE ABDOMINAL IRRADIATION FOR PATIENTS WITH RECURRENT OR PERSISTENT DISEASE AFTER COMBINATION CHEMOTHERAPY** *JOURNAL OF CLINICAL ONCOLOGY*
SCHRAY, M. F., Martinez, A., HOWES, A. E., Podratz, K. C., Ballon, S. C., Malkasian, G. D., Sikic, B. I.
1988; 6 (9): 1433-1439
- **ENHANCEMENT OF THE CLINICAL ACTIVITY OF MELPHALAN BY THE HYPOXIC CELL SENSITIZER MISONIDAZOLE** *CANCER RESEARCH*
Coleman, C. N., Carlson, R. W., Halsey, J., Kohler, M., Gribble, M., Sikic, B. I., Jacobs, C.
1988; 48 (12): 3528-3532
- **DOXORUBICIN AND THE ALKYLATING ANTHRACYCLINE 3'-DEAMINO-3'-(3-CYANO-4-MORPHOLINYL) DOXORUBICIN - COMPARATIVE INVITRO POTENCY AGAINST LEUKEMIA AND BONE-MARROW CELLS** *JOURNAL OF THE NATIONAL CANCER INSTITUTE*
Beckman, R. A., MCFALL, P. J., Sikic, B. I., Smith, S. D.
1988; 80 (5): 361-365
- **ANTIBODY-DIRECTED TARGETING OF LIPOSOMES TO HUMAN CELL-LINES - ROLE OF BINDING AND INTERNALIZATION ON GROWTH-INHIBITION** *CANCER RESEARCH*
Berinstein, N., Matthay, K. K., Papahadjopoulos, D., Levy, R., Sikic, B. I.
1987; 47 (22): 5954-5959
- **A THERAPY PLANNING ARCHITECTURE THAT COMBINES DECISION-THEORY AND ARTIFICIAL-INTELLIGENCE TECHNIQUES** *COMPUTERS AND BIOMEDICAL RESEARCH*
Langlotz, C. P., Fagan, L. M., Tu, S. W., Sikic, B. I., Shortliffe, E. H.
1987; 20 (3): 279-303
- **CHARACTERIZATION AND IMMUNOASSAY OF HUMAN TUMOR-ASSOCIATED GALACTOSYLTRANSFERASE ISOENZYME-II**
Brandt, A. E., Winant, R. C., Uemura, M., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.1987: 181-181
- **RESISTANCE AND CROSS-RESISTANCE STUDIES OF CYANOMORPHOLINO DOXORUBICIN (MRA-CN)**
Scudder, S. A., EHSAN, M. N., Tan, Y. O., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.1987: 295-295
- **DIFFERENTIAL PROTECTIVE EFFECTS OF VARYING DEGREES OF HYPOXIA ON THE CYTOTOXICITIES OF ETOPOSIDE AND BLEOMYCIN** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Yamauchi, T., Raffin, T. A., Yang, P., Sikic, B. I.
1987; 19 (4): 282-286

- **CHARACTERIZATION AND IMMUNOASSAY OF HUMAN TUMOR-ASSOCIATED GALACTOSYLTRANSFERASE ISOENZYME-II**
Brandt, A. E., Winant, R. C., Uemura, M., Sikic, B. I.
WILEY-LISS.1987: 158-158
- **HIGH-DOSE MEGESTROL-ACETATE THERAPY OF OVARIAN-CARCINOMA - A PHASE-II STUDY BY THE NORTHERN CALIFORNIA ONCOLOGY GROUP** *SEMINARS IN ONCOLOGY*
Sikic, B. I., Scudder, S. A., Ballon, S. C., SORIERO, O. M., CHRISTMAN, J. E., SUEY, L., EHSAN, M. N., Brandt, A. E., Evans, T. L.
1986; 13 (4): 26-32
- **ADVANCED EPITHELIAL OVARIAN-CANCER - TOXICITY OF WHOLE ABDOMINAL IRRADIATION AFTER OPERATION, COMBINATION CHEMOTHERAPY, AND REOPERATION** *GYNECOLOGIC ONCOLOGY*
SCHRAY, M. F., Martinez, A., HOWES, A. E., Ballon, S. C., Podratz, K. C., Sikic, B. I., Malkasian, G. D.
1986; 24 (1): 68-80
- **VERAPAMIL-MEDIATED SENSITIZATION OF DOXORUBICIN-SELECTED PLEIOTROPIC RESISTANCE IN HUMAN SARCOMA-CELLS - SELECTIVITY FOR DRUGS WHICH PRODUCE DNA SCISSION** *CANCER RESEARCH*
Harker, W. G., Bauer, D., ETIZ, B. B., Newman, R. A., Sikic, B. I.
1986; 46 (5): 2369-2373
- **INVITRO SELECTION AND CHARACTERIZATION OF A BLEOMYCIN-RESISTANT SUBLINE OF B-16 MELANOMA** *CANCER RESEARCH*
ZUCKERMAN, J. E., Raffin, T. A., Brown, J. M., Newman, R. A., ETIZ, B. B., Sikic, B. I.
1986; 46 (4): 1748-1753
- **NEUROLOGIC DYSFUNCTION IN PATIENTS TREATED FOR SMALL CELL-CARCINOMA OF THE LUNG - A CLINICAL AND RADIOLOGICAL STUDY** *INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS*
CHAK, L. Y., ZATZ, L. M., Wasserstein, P., Cox, R. S., KUSHLAN, P. D., PORZIG, K. J., Sikic, B. I.
1986; 12 (3): 385-389
- **BIOCHEMICAL AND CELLULAR DETERMINANTS OF BLEOMYCIN CYTOTOXICITY** *CANCER SURVEYS*
Sikic, B. I.
1986; 5 (1): 81-91
- **PRELIMINARY-OBSERVATIONS OF INTRAPERITONEAL CARBOPLATIN PHARMACOKINETICS DURING A PHASE-I STUDY OF THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
DeGregorio, M. W., Lum, B. L., Holleran, W. M., WILBUR, B. J., Sikic, B. I.
1986; 18 (3): 235-238
- **BLEOMYCIN, MITOMYCIN, AND CISPLATIN THERAPY FOR ADVANCED SQUAMOUS CARCINOMA OF THE UTERINE CERVIX - A PHASE-II STUDY OF THE NORTHERN-CALIFORNIA-ONCOLOGY-GROUP** *CANCER TREATMENT REPORTS*
Picozzi, V. J., Sikic, B. I., Carlson, R. W., Koretz, M., Ballon, S. C.
1985; 69 (7-8): 903-905
- **ADVANCED EPITHELIAL OVARIAN-CANCER - WHOLE ABDOMINAL IRRADIATION FOR PATIENTS WITH RECURRENT OR PERSISTENT DISEASE FOLLOWING CHEMOTHERAPY**
Schray, M., Martinez, A., Howes, A., PODRATZ, K., Ballon, S., Sikic, B., MALKASIAN, G.
LIPPINCOTT-RAVEN PUBL.1985: 12-13
- **CISPLATIN, DOXORUBICIN, AND CYCLOPHOSPHAMIDE CHEMOTHERAPY FOR ADVANCED ENDOMETRIAL CARCINOMA** *CANCER TREATMENT REPORTS*
Turbow, M. M., Ballon, S. C., Sikic, B. I., KORETZ, M. M.
1985; 69 (5): 465-467
- **CENTRAL NERVOUS-SYSTEM TOXICITY AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF INTRAVENTRICULARLY ADMINISTERED BLEOMYCIN IN BEAGLES** *CANCER RESEARCH*
Levin, V. A., Byrd, D., Sikic, B. I., ETIZ, B. B., Campbell, J., BORCICH, J. K., Davis, R. L.
1985; 45 (8): 3810-3815
- **GASTRIN RELEASING PEPTIDE IS A SELECTIVE MITOGEN FOR SMALL CELL LUNG-CARCINOMA INVITRO** *JOURNAL OF CLINICAL INVESTIGATION*
Weber, S., ZUCKERMAN, J. E., Bostwick, D. G., Bensch, K. G., Sikic, B. I., Raffin, T. A.
1985; 75 (1): 306-309

- **2ND-LOOK LAPAROTOMY IN EPITHELIAL OVARIAN-CARCINOMA - PRECISE DEFINITION, SENSITIVITY, AND SPECIFICITY OF THE OPERATIVE PROCEDURE** *GYNECOLOGIC ONCOLOGY*
Ballon, S. C., PORTNUFF, J. C., Sikic, B. I., Turbow, M. M., Teng, N. N., SORIERO, O. M.
1984; 17 (2): 154-160
- **DIFFERENTIAL PROTECTIVE EFFECTS OF VARYING DEGREES OF HYPOXIA ON THE CYTOTOXICITIES OF ETOPOSIDE AND BLEOMYCIN**
Yamauchi, T., Raffin, T. A., Weber, S., ZUCKERMAN, J. E., Yang, P., Sikic, B. I.
AMER COLL CHEST PHYSICIANS.1984: 311-11
- **CHEMOTHERAPY OF SMALL-CELL CARCINOMA OF LUNG - A RANDOMIZED COMPARISON OF ALTERNATING AND SEQUENTIAL COMBINATION CHEMOTHERAPY PROGRAMS** *JOURNAL OF CLINICAL ONCOLOGY*
Daniels, J. R., CHAK, L. Y., Sikic, B. I., Lockbaum, P., Kohler, M., Carter, S. K., Reynolds, R., Bohnen, R., Gandara, D., Yu, J.
1984; 2 (11): 1192-1199
- **INCREASED INCIDENCE OF ACUTE NONLYMPHOCYTIC LEUKEMIA FOLLOWING THERAPY IN PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG** *JOURNAL OF CLINICAL ONCOLOGY*
CHAK, L. Y., Sikic, B. I., TUCKER, M. A., Horns, R. C., Cox, R. S.
1984; 2 (5): 385-390
- **DIFFERENTIAL PROTECTIVE EFFECTS OF VARYING DEGREES OF HYPOXIA ON THE CYTOTOXICITIES OF ETOPOSIDE AND BLEOMYCIN**
Yamauchi, T., Raffin, T. A., Weber, S., ZUCKERMAN, J. E., Yang, P., Sikic, B. I.
AMER COLL CHEST PHYSICIANS.1984: 311-11
- **CHEMOTHERAPY OF SMALL-CELL CARCINOMA OF LUNG - A RANDOMIZED COMPARISON OF ALTERNATING AND SEQUENTIAL COMBINATION CHEMOTHERAPY PROGRAMS** *JOURNAL OF CLINICAL ONCOLOGY*
Daniels, J. R., CHAK, L. Y., Sikic, B. I., Lockbaum, P., Kohler, M., Carter, S. K., Reynolds, R., Bohnen, R., Gandara, D., Yu, J.
1984; 2 (11): 1192-1199
- **INCREASED INCIDENCE OF ACUTE NONLYMPHOCYTIC LEUKEMIA FOLLOWING THERAPY IN PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG** *JOURNAL OF CLINICAL ONCOLOGY*
CHAK, L. Y., Sikic, B. I., TUCKER, M. A., Horns, R. C., Cox, R. S.
1984; 2 (5): 385-390
- **CONTINUOUS INFUSION OR BOLUS INJECTION IN CANCER-CHEMOTHERAPY** *ANNALS OF INTERNAL MEDICINE*
Carlson, R. W., Sikic, B. I.
1983; 99 (6): 823-833
- **COMBINATION CISPLATIN, VINBLASTINE, AND BLEOMYCIN CHEMOTHERAPY (PVB) FOR MALIGNANT GERM-CELL TUMORS OF THE OVARY** *JOURNAL OF CLINICAL ONCOLOGY*
Carlson, R. W., Sikic, B. I., Turbow, M. M., Ballon, S. C.
1983; 1 (10): 645-651
- **PULMONARY TOXICITY OF ANTITUMOR AGENTS** *CANCER TREATMENT REVIEWS*
Muggia, F. M., Louie, A. C., Sikic, B. I.
1983; 10 (4): 221-243
- **DIAGNOSTIC ACCURACIES OF CLINICAL-STUDIES IN PATIENTS WITH SMALL CELL-CARCINOMA OF THE LUNG** *JOURNAL OF CLINICAL ONCOLOGY*
CHAK, L. Y., PARYANI, S. B., Sikic, B. I., Lockbaum, P., Torti, F. M., Carter, S. K.
1983; 1 (5): 290-294
- **ABSORPTION OF ANTI-NEOPLASTIC DRUGS FOLLOWING LARGE-VOLUME LP ADMINISTRATION TO RATS** *CANCER TREATMENT REPORTS*
LITTERST, C. L., Torres, I. J., Arnold, S., McGunagle, D., FURNER, R., Sikic, B. I., Guarino, A. M.
1982; 66 (1): 147-155
- **HUMAN-TUMOR CLONOGENIC ASSAYS - STUDIES OF GROWTH AND DRUG SENSITIVITY**
Sikic, B. I., Evans, T. L., MacKintosh, F. R., Smith, H. S.
AMER ASSOC CANCER RESEARCH.1982: 186-86
- **PATTERNS OF FAILURE IN SMALL CELL-CARCINOMA OF THE LUNG** *CANCER*

- CHAK, L. Y., Daniels, J. R., Sikic, B. I., Torti, F. M., Lockbaum, P., Carter, S. K.
1982; 50 (9): 1857-1863
- **PULMONARY-DISEASE AS A COMPLICATION OF CHLOROZOTOCIN CHEMOTHERAPY** *CANCER TREATMENT REPORTS*
Ahlgren, J. D., Smith, F. P., KERWIN, D. M., Sikic, B. I., Weiner, J. H., SCHEIN, P. S.
1981; 65 (3-4): 223-229
 - **BLEOMYCIN HYDROLASE KINETICS IN THE CYTOSOL OF MALIGNANT AND NORMAL-TISSUES**
Sikic, B. I., Evans, T. L.
AMER ASSOC CANCER RESEARCH.1981: 239-39
 - **CLONAL HETEROGENEITY IN A HUMAN OVARIAN ADENOCARCINOMA**
MacKintosh, F. R., Louie, A. C., Evans, T. L., Amylon, M. D., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.1981: 379-79
 - **HUMAN-TUMOR CLONOGENIC ASSAYS - AN OVERVIEW** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
Sikic, B. I., Taber, R. L.
1981; 6 (3): 201-203
 - **METHODOLOGIC PROBLEMS IN CLONOGENIC ASSAYS OF SPONTANEOUS HUMAN-TUMORS** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
MacKintosh, F. R., Evans, T. L., Sikic, B. I.
1981; 6 (3): 205-210
 - **RELATIVE PULMONARY TOXICITY AND ANTI-TUMOR EFFECTS OF 2 NEW BLEOMYCIN ANALOGS, PEPELOMYCIN AND TALLYSOMYCIN-A** *CANCER TREATMENT REPORTS*
Sikic, B. I., SIDDIK, Z. H., Gram, T. E.
1980; 64 (4-5): 659-667
 - **INTERACTION OF OTHER ANTI-CANCER DRUGS WITH BLEOMYCIN IN AN ANIMAL-MODEL OF PULMONARY TOXICITY**
Louie, A. C., Evans, T. L., Sikic, B. I.
AMER ASSOC CANCER RESEARCH.1980: 290-90
 - **HEPATIC CYTOCHROME P-450-DEPENDENT METABOLISM AND ENZYMATIC CONJUGATION OF FOREIGN COMPOUNDS IN VITAMIN-A-DEFICIENT RATS** *PHARMACOLOGY*
SIDDIK, Z. H., Drew, R., LITTERST, C. L., Mimnaugh, E. G., Sikic, B. I., Gram, T. E.
1980; 21 (6): 383-390
 - **PHARMACOKINETICS AND PROTEIN-BINDING OF CIS-DICHLORODIAMMINE PLATINUM (II) ADMINISTERED AS A ONE-HOUR OR AS A 20-HOUR INFUSION** *CANCER CHEMOTHERAPY AND PHARMACOLOGY*
GULLO, J. J., LITTERST, C. L., Maguire, P. J., Sikic, B. I., Hoth, D. F., Woolley, P. V.
1980; 5 (1): 21-26
 - **LIPOSOMAL PROTECTION OF ADRIAMYCIN-INDUCED CARDIOTOXICITY IN MICE** *CANCER RESEARCH*
Rahman, A., KESSLER, A., More, N., Sikic, B., Rowden, G., Woolley, P., SCHEIN, P. S.
1980; 40 (5): 1532-1537
 - **LACK OF CORRELATION BETWEEN CORTISOL-INDUCED PRECOCIOUS MATURATION OF THE FETAL RABBIT LUNG AND DRUG-METABOLISM** *BIOCHEMICAL PHARMACOLOGY*
SIDDIK, Z. H., Sikic, B. I., Drew, R., Mimnaugh, E. G., LITTERST, C. L., Gram, T. E.
1979; 28 (5): 683-685
 - **EFFECTS OF ALPHA-TOCOPHEROL ON THE TOXICITY, DISPOSITION, AND METABOLISM OF ADRIAMYCIN IN MICE** *TOXICOLOGY AND APPLIED PHARMACOLOGY*
Mimnaugh, E. G., SIDDIK, Z. H., Drew, R., Sikic, B. I., Gram, T. E.
1979; 49 (1): 119-126
 - **ENHANCEMENT OF BLEOMYCIN ACTIVITY AGAINST LEWIS LUNG-TUMORS IN MICE BY LOCAL HYPERTHERMIA** *CANCER RESEARCH*
Magin, R. L., Sikic, B. I., Cysyk, R. L.
1979; 39 (9): 3792-3795

- **DISTRIBUTION OF IMIPRAMINE-C-14 IN MICE BEARING LEWIS LUNG-CARCINOMA** *LIFE SCIENCES*
Drew, R., Sikic, B. I., Mimnaugh, E. G., LITTERST, C. L., Gram, T. E.
1979; 25 (21): 1813-1820
- **INVITRO DRUG-METABOLISM IN MALE AND FEMALE ATHYMIC, NUDE-MICE** *LIFE SCIENCES*
LITTERST, C. L., Sikic, B. I., Mimnaugh, E. G., Guarino, A. M., Gram, T. E.
1978; 22 (19): 1723-1730
- **EFFECT OF WHOLE-BODY HYPERTHERMIA ON DISPOSITION AND METABOLISM OF ADRIAMYCIN IN RABBITS** *CANCER RESEARCH*
Mimnaugh, E. G., WARING, R. W., Sikic, B. I., Magin, R. L., Drew, R., LITTERST, C. L., Gram, T. E., Guarino, A. M.
1978; 38 (5): 1420-1425
- **EFFECTS OF ASCORBIC-ACID DEFICIENCY AND REPLETION ON PULMONARY, RENAL, AND HEPATIC DRUG-METABOLISM IN GUINEA-PIG** *ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS*
Sikic, B. I., Mimnaugh, E. G., LITTERST, C. L., Gram, T. E.
1977; 179 (2): 663-671
- **EFFECTS OF DIETARY ASCORBIC-ACID SUPPLEMENTATION ON HEPATIC DRUG-METABOLIZING-ENZYMES IN GUINEA-PIG** *BIOCHEMICAL PHARMACOLOGY*
Sikic, B. I., Mimnaugh, E. G., Gram, T. E.
1977; 26 (21): 2037-2041
- **INTERACTION OF FLURAZEPAM WITH DIPHENYLHYDANTOIN IN RAT** *DRUG METABOLISM AND DISPOSITION*
Sikic, B. I., BAUMEL, I. P.
1976; 4 (6): 584-586
- **REPEAT ADMINISTRATION OF MARIJUANA SMOKE TO HUMANS** *ARCHIVES OF GENERAL PSYCHIATRY*
RENAULT, P. F., Schuster, C. R., FREEDMAN, D. X., Sikic, B., NEBELDEM, D., Halaris, A.
1974; 31 (1): 95-102
- **EVALUATION OF A PROGRAM FOR TREATMENT OF ALCOHOLISM IN CROATIA** *INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY*
Sikic, B. I., Walker, R. D., PETERSON, D. R.
1972; 18 (3): 171-182